Next Article in Journal
Results of surgical treatment of aortic root infection
Previous Article in Journal
The evaluation of knowledge and activities of primary health care professionals in promoting breast-feeding
 
 
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Use of recombinant activated factor VII

by
Dagmara Reingardienė
1,* and
Robertas Lažauskas
2
1
Department of Intensive Care
2
Department of Physiology, Kaunas University of Medicine, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2009, 45(3), 248; https://doi.org/10.3390/medicina45030032
Submission received: 20 October 2008 / Accepted: 11 February 2009 / Published: 16 February 2009

Abstract

Recombinant activated factor VII (rFVIIa) has been used in the treatment of various congenital and acquired hemostatic disorders for more than 10 years. Hemostasis is initiated by the FVIIa bound to tissue factor (TF), which constitutes only approximately 1% of total amount of the FVII protein existing in the blood. rFVII becomes activated only after the binding to the TF, released at the site of tissue injury. The efficiency of rFVIIa in the treatment of such life-threatening hemorrhagic states like hemophilia reaches up to 76–84%. rFVIIa is successfully used in the treatment of congenital deficiency of factor VII. It normalizes prothrombin time in the patients with the liver diseases and in cases of overdose of indirect anticoagulants. It is also useful for patients suffering from thrombocytopenia, thrombocyte function disorders, hemophilia A and B with development of inhibitors. rFVIIa allows overcoming uncontrollable hemorrhages, etc. It is supposed that rFVIIa is becoming a universal hemostatic drug.
Keywords: hemorrhage; hemostasis; bleeding; hemophilia; recombinant activated factor VII hemorrhage; hemostasis; bleeding; hemophilia; recombinant activated factor VII

Share and Cite

MDPI and ACS Style

Reingardienė, D.; Lažauskas, R. Use of recombinant activated factor VII. Medicina 2009, 45, 248. https://doi.org/10.3390/medicina45030032

AMA Style

Reingardienė D, Lažauskas R. Use of recombinant activated factor VII. Medicina. 2009; 45(3):248. https://doi.org/10.3390/medicina45030032

Chicago/Turabian Style

Reingardienė, Dagmara, and Robertas Lažauskas. 2009. "Use of recombinant activated factor VII" Medicina 45, no. 3: 248. https://doi.org/10.3390/medicina45030032

APA Style

Reingardienė, D., & Lažauskas, R. (2009). Use of recombinant activated factor VII. Medicina, 45(3), 248. https://doi.org/10.3390/medicina45030032

Article Metrics

Back to TopTop